Therefore, DHM may inhibit the activation of ERK1/2 pathway by decreasing the expression of P2X7 receptor, reducing the secretion of inflammatory cytokines in peripheral glial cells, restraining pain and depression transduction, and thereby alleviating the symptoms of pain and depression. Here, MAPK3 is linked to depressive symptom measurement.